VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

As previously reported, Wedbush analyst Robert Driscoll downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Arvinas and Pfizer will share the costs and profits of the development and commercialization of vepdegestrant, which has ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...